Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly v. IPPI

Executive Summary

Lilly v. IPPI: Oncovin-manufacturer Lilly met with FDA to discuss agency approval of International Pharmaceutical Products Inc.'s vincristine. According to an agency memo of the meeting, Lilly's Washington counsel urged FDA to rescind approval of the generic anticancer agent on the grounds that IPPI still had not satisfied patent certification and notification requirements. FDA previously rescinded approval of IPPI's ANDA for vincristine until the generic company submitted Lilly patent information ("The Pink Sheet" Feb. 2, T&G-5). The memo reports that FDA Chief Counsel Thomas Scarlett replied "he was not prepared to recommend that IPPI's approval be rescinded a second time but that FDA will try to improve its procedures for handling patent filings and certifications".
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS011836

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel